EA201791321A1 - Составы ингибитора lfa-1 - Google Patents

Составы ингибитора lfa-1

Info

Publication number
EA201791321A1
EA201791321A1 EA201791321A EA201791321A EA201791321A1 EA 201791321 A1 EA201791321 A1 EA 201791321A1 EA 201791321 A EA201791321 A EA 201791321A EA 201791321 A EA201791321 A EA 201791321A EA 201791321 A1 EA201791321 A1 EA 201791321A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
lfa
inhibitor
formula
methods
Prior art date
Application number
EA201791321A
Other languages
English (en)
Russian (ru)
Inventor
Мэри Ньюман
Уилльям Ханке
Original Assignee
Саркоуд Байосайенс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791321(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саркоуд Байосайенс Инк. filed Critical Саркоуд Байосайенс Инк.
Publication of EA201791321A1 publication Critical patent/EA201791321A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA201791321A 2012-12-19 2013-12-18 Составы ингибитора lfa-1 EA201791321A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
EA201791321A1 true EA201791321A1 (ru) 2018-04-30

Family

ID=50979140

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791321A EA201791321A1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1
EA201591180A EA028008B1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201591180A EA028008B1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP2934510B1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA201791321A1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX368876B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
CN114025759A (zh) * 2019-04-18 2022-02-08 阿祖拉眼科有限公司 用于治疗眼病的化合物和方法
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
EP4232034A4 (en) * 2020-10-21 2024-12-04 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR TREATING EYE DISORDERS
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
WO2025104294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
HK1004520A1 (en) * 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
CN101175488B (zh) * 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
JP5315051B2 (ja) * 2005-07-08 2013-10-16 千寿製薬株式会社 オロパタジンを含む眼科用経皮吸収型製剤
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
JP2011518155A (ja) 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
CA2737475A1 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CN102176920B (zh) * 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
JP5659388B2 (ja) * 2009-06-10 2015-01-28 マイトテック ソシエテ アノニム 医学及び獣医眼科の使用のための医薬組成物
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
PH12012501098A1 (en) * 2009-11-23 2014-10-14 Allergan Inc 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
US20120190653A1 (en) 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
WO2012111029A2 (en) * 2011-02-18 2012-08-23 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
WO2013148896A1 (en) * 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
DK2934510T3 (da) 2021-01-25
US20220000859A1 (en) 2022-01-06
CA2894170A1 (en) 2014-06-26
EP2934510B1 (en) 2020-10-28
BR112015014367B1 (pt) 2022-11-22
KR20150100763A (ko) 2015-09-02
JP6373867B2 (ja) 2018-08-15
PT2934510T (pt) 2021-01-13
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
PL2934510T3 (pl) 2021-07-05
ZA201608069B (en) 2017-11-29
SI2934510T1 (sl) 2021-02-26
ZA201504404B (en) 2020-01-29
BR112015014367A2 (pt) 2017-07-11
US20150320737A1 (en) 2015-11-12
EP2934510A1 (en) 2015-10-28
MX2015007540A (es) 2016-04-13
CA2894170C (en) 2021-08-10
KR101891144B1 (ko) 2018-08-23
IL239490A0 (en) 2015-08-31
CN104955453A (zh) 2015-09-30
CN104955453B (zh) 2018-09-18
AU2013361579A1 (en) 2015-06-18
HUE052299T2 (hu) 2021-04-28
WO2014100135A1 (en) 2014-06-26
ES2846724T3 (es) 2021-07-29
MX2019012375A (es) 2020-01-20
MX368876B (es) 2019-10-21
NZ708821A (en) 2020-03-27
JP2016503058A (ja) 2016-02-01
EP3827823A1 (en) 2021-06-02
MX391620B (es) 2025-03-19
IL239490B (en) 2018-12-31
EA201591180A1 (ru) 2015-12-30
HK1214536A1 (zh) 2016-07-29
AU2013361579B2 (en) 2018-05-24
EA028008B1 (ru) 2017-09-29
US11058677B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
EA201791321A1 (ru) Составы ингибитора lfa-1
MD20130095A2 (ro) Compuşi condensaţi de benzoxazepinone ca modulatori ai canalelor ionice
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201792421A1 (ru) Амидозамещенные производные циклогексана
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201290919A1 (ru) Индазольные соединения и их применение
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201691881A1 (ru) Новые соединения
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата